Levee Medical Clinches $10 Million for Innovative Prostate Surgery Solutions
On February 11, 2025, Levee Medical, a pioneering medical device company, announced the successful completion of its Series B funding round, raising over $10 million to enhance surgical outcomes for prostate cancer patients. The influx of over $14 million, which includes note conversions, underscores considerable investor confidence in the company’s innovative approach to addressing post-prostatectomy incontinence, a condition that affects many men after prostate surgery.
The funding will be directed toward the further development of the Voro® Urologic Scaffold, a groundbreaking absorbable device designed specifically to mitigate urinary incontinence following prostate cancer surgery. Prostatectomy patients often face challenges with incontinence, affecting their quality of life; thus, this device aims to directly address such issues. Not only will the funds bolster the ongoing clinical studies, including a pivotal trial in the United States, but it will also support current research endeavors involving the ARID study on the device's effectiveness.
"We are incredibly grateful for the strong support from our investors, as our work focuses on delivering transformative solutions that significantly improve patient outcomes," remarked Adam Irving, CEO of Levee Medical. He highlighted the significant developments underway that give hope to many men struggling with post-surgical incontinence.
Among the promising advancements detailed by the company, notable progress has been marked in the ARID study, particularly at the Hospital Nacional in Panama City, where Principal Investigator Dr. Gustavo Espino has successfully enrolled 28 patients. This phase of research aims to assess both the safety and efficacy of the Voro Urologic Scaffold in minimizing post-surgical urinary incontinence, with early feedback indicating positive outcomes from the patients involved.
Dr. Espino shared his enthusiastic observations about the Voro device, stating, "Our experience has shown outstanding safety results, and patients have reported early improvements in their continence, which significantly enhances their quality of life post-surgery." These early indicators suggest that the Voro Scaffold is on the right path to making a notable impact in urological health post-prostatectomy.
The Voro Urologic Scaffold is meticulously designed to be utilized during the surgical procedure itself, with the objective of properly managing the bladder neck’s geometry and maintaining urethral length—two critical aspects that contribute to preventing incontinence after surgery. This innovative, absorbable solution holds the potential of greatly decreasing the occurrence of stress urinary incontinence, promising improvements for patients who undergo radical prostatectomy.
For those interested in the broader context of the company's endeavors, it is essential to understand that the Voro Urologic Scaffold is currently classified as an investigational device, pending clearance by the FDA, and remains in the research and development phase. This device is not yet available for commercial sale.
Levee Medical is firmly committed to crafting advanced medical solutions aimed at reducing the complications commonly associated with surgical interventions in prostate cancer treatment. As the organization progresses in its mission, the ongoing support from its investors and the scientific community will be pivotal for the successful realization of the Voro Urologic Scaffold and other future devices expected to follow.
For further insights and updates regarding Levee Medical's activities and their groundbreaking work on prostate cancer treatment devices, interested parties can explore their official website at leveemedical.com. The company's efforts, aligned with their pursuit to alleviate critical post-surgery challenges for patients, highlight a significant breakthrough in the medical technology landscape focused on men's health issues.
The funding will be directed toward the further development of the Voro® Urologic Scaffold, a groundbreaking absorbable device designed specifically to mitigate urinary incontinence following prostate cancer surgery. Prostatectomy patients often face challenges with incontinence, affecting their quality of life; thus, this device aims to directly address such issues. Not only will the funds bolster the ongoing clinical studies, including a pivotal trial in the United States, but it will also support current research endeavors involving the ARID study on the device's effectiveness.
"We are incredibly grateful for the strong support from our investors, as our work focuses on delivering transformative solutions that significantly improve patient outcomes," remarked Adam Irving, CEO of Levee Medical. He highlighted the significant developments underway that give hope to many men struggling with post-surgical incontinence.
Among the promising advancements detailed by the company, notable progress has been marked in the ARID study, particularly at the Hospital Nacional in Panama City, where Principal Investigator Dr. Gustavo Espino has successfully enrolled 28 patients. This phase of research aims to assess both the safety and efficacy of the Voro Urologic Scaffold in minimizing post-surgical urinary incontinence, with early feedback indicating positive outcomes from the patients involved.
Dr. Espino shared his enthusiastic observations about the Voro device, stating, "Our experience has shown outstanding safety results, and patients have reported early improvements in their continence, which significantly enhances their quality of life post-surgery." These early indicators suggest that the Voro Scaffold is on the right path to making a notable impact in urological health post-prostatectomy.
The Voro Urologic Scaffold is meticulously designed to be utilized during the surgical procedure itself, with the objective of properly managing the bladder neck’s geometry and maintaining urethral length—two critical aspects that contribute to preventing incontinence after surgery. This innovative, absorbable solution holds the potential of greatly decreasing the occurrence of stress urinary incontinence, promising improvements for patients who undergo radical prostatectomy.
For those interested in the broader context of the company's endeavors, it is essential to understand that the Voro Urologic Scaffold is currently classified as an investigational device, pending clearance by the FDA, and remains in the research and development phase. This device is not yet available for commercial sale.
Levee Medical is firmly committed to crafting advanced medical solutions aimed at reducing the complications commonly associated with surgical interventions in prostate cancer treatment. As the organization progresses in its mission, the ongoing support from its investors and the scientific community will be pivotal for the successful realization of the Voro Urologic Scaffold and other future devices expected to follow.
For further insights and updates regarding Levee Medical's activities and their groundbreaking work on prostate cancer treatment devices, interested parties can explore their official website at leveemedical.com. The company's efforts, aligned with their pursuit to alleviate critical post-surgery challenges for patients, highlight a significant breakthrough in the medical technology landscape focused on men's health issues.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.